In a study by Tie et al. [17], a higher prevalence of KRAS mutations in lung versus liver metastases was found (62% vs. 32%, p = 0.003), and a higher risk of lung relapse was evidenced among those with KRAS-mutated primary tumours (HR = 2.1, p = 0.007). This evidence concerns the gene KRAS and neoplasm.